---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-129238"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2024-11-20T23:59:59+00:00"
generated_at: "2026-05-29T22:04:32.673075+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# PYX-201 achieves 50% ORR in HNSCC; Merck collaboration for KEYTRUDA combo

## Summary
- PYX-201 achieved 50% confirmed ORR by RECIST 1.1 (1 CR, 2 PR) and 100% DCR in 6 heavily pretreated HNSCC patients.
- Overall 26% ORR across six solid tumor types (n=31) with dose-dependent responses; ovarian, NSCLC, breast, sarcoma also showed shrinkage.
- Entered Clinical Trial Collaboration with Merck to evaluate PYX-201 + KEYTRUDA in HNSCC, HR+/HER2- breast, TNBC, sarcoma; dosing starts Q1 2025.
- PYX-201 generally well-tolerated; low incidence of Grade 3/4 TRAEs; favorable PK profile with increased stability.
- Multiple Phase 1 expansion studies and combo studies to begin Q1 2025 with data readouts expected throughout 2025 and 2026.

## SEC filing metadata
- accession: 0000950170-24-129238
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2024-11-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000095017024129238/0000950170-24-129238-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000095017024129238/pyxs-20241120.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-129238
- JSON: https://secwatch.observer/filing/0000950170-24-129238.json
- Plain text: https://secwatch.observer/filing/0000950170-24-129238.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.